## HCV FLOWSHEET-RIBAVIRIN/SOFOSBUVIR (+/-PEGYLATED IFN) (+/-SIMEPREVIR) CDCR 7416-1 (03/14)

Form: Pa	ige 1 of 1
----------	------------

1 (03/14)													. •	rage rorr
Baseline	2 Week DATE:	4 Week DATE:	8 Week DATE:	12 Week DATE:	16 Week* DATE:	20 Week* DATE:	24 Week* DATE:	28 Week* DATE:	32 Week* DATE:	36 Week* DATE:	40 Week* DATE:	44 Week* DATE:	48 Week* DATE:	12 wk. post- tx DATE:
	Baseline	Baseline 2 Week DATE:	Baseline 2 Week DATE: DATE:	Baseline  2 Week DATE: D	Baseline    2 Week DATE:	Baseline  2 Week DATE: D	Baseline    2 Week DATE:	Baseline    2 Week DATE:	2 Week   2 Week   2 Week   DATE:   D	2   Week   DATE:   A   Week   DATE:   DATE:	2 Week   4 Week   DATE:   DA	2 Week 4 Week 8 Week 12 Week 16 Week* 20 Week* 24 Week* 28 Week* 32 Week* 36 Week* 40 Week*	2   Week   2   Week   DATE:   DATE:	Baseline    2   Week   DATE:   DATE:

SOFOSBUVIR PRESCRIBING RECOMMENDATIONS (Abbreviations: PEG: pegylated interferon; RBV: ribavirin; SOF sofosbuvir; SMV \*\*\*simeprevir; exp experienced)

PATIENT TYPE	REGIMEN	TREATMENT DURATION
Treatment naive Genotype 1	PEG and weight based RBV and SOF	12 weeks
Treatment naive Genotype 2 or 3 - HIV positive	Weight based RBV and SOF	Genotype 2: 12 weeks; Genotype 2 with cirrhosis: 16 weeks Genotype 3: 24 weeks
Treatment naive Genotype 4	PEG and weight based RBV and SOF	12 weeks
PEG ineligible Genotype 1	SMV and SOF +/- Weight based RBV	12 weeks
PEG ineligible Genotype 2,3,4,5,6	Weight based RBV and SOF	Genotype 2: 12 weeks Genotype 3,4,5,6: 24 weeks
Treatment exp Genotype 1	PEG and weight based RBV and SOF	SOF 12 weeks, PEG/RBV 12-24 weeks; DAA exp: Genotype 1a: 12 weeks; Genotype 1b: SOF 12 weeks, 24 weeks PEG/RBV
Treatment exp Genotype 2,3	Weight based RBV and SOF	Genotype 2: 12 weeks; Genotype 2: with cirrhosis 16 weeks Genotype 3: 24 weeks
Treatment exp Genotype 4,5,6	PEG and weight based RBV and SOF	12 weeks

*If on	treatmen
** If o	n PFG

CDCR #:	
Last Name:	
First Name:	MI:
DOB:	

<sup>\*\*\*</sup>Nonformulary